KMC
HAE icon

Kirr Marbach & Co’s Haemonetics HAE Stock Holding History

Kirr Marbach & Co’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-11,300
Closed -$446K – 84
2017
Q2 		$446K Buy
11,300
+4,070
+56% +$167K 0.1% 53
2017
Q1 		$293K Buy
7,230
+80
+1% +$3.12K 0.07% 53
2016
Q4 		$287K Sell
7,150
-380
-5% -$14.3K 0.06% 54
2016
Q3 		$273K Buy
7,530
+270
+4% +$9.27K 0.05% 57
2016
Q2 		$210K Buy
+7,260
New +$219K 0.05% 64

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Kirr Marbach & Co's HAE Position: Q3 2017 in Review

Kirr Marbach & Co sold out of Haemonetics (HAE) in Q3 2017, closing a stake of 11,300 shares — an estimated $446K sold.

Kirr Marbach & Co first reported a position in HAE in Q2 2016 and held it in 5 quarters. The position peaked at $446K in Q2 2017. 207 funds tracked by Wall St. Rank hold HAE as of Q3 2017.

  • Kirr Marbach & Co reported no remaining Haemonetics position as of Q3 2017 after selling out during the quarter.
  • Kirr Marbach & Co sold 11,300 Haemonetics shares in Q3 2017, an estimated $446K.
  • Kirr Marbach & Co first reported a position in Haemonetics in Q2 2016 and held it in 5 quarters.
  • Kirr Marbach & Co's Haemonetics position peaked at $446K in Q2 2017.
  • 207 funds tracked by Wall St. Rank held Haemonetics as of Q3 2017.

Based on Kirr Marbach & Co's 13F filing for Q3 2017, filed 23 Oct 2017.